Evidence map›Paper›PMID 38183010›Full record

ReviewBMC microbiology2024

Microbiome as a biomarker and therapeutic target in pancreatic cancer.

Ghazaleh Pourali, Danial Kazemi, Amir Shayan Chadeganipour, Mahshid Arastonejad, Sara Naghizadeh Kashani, Roozbeh Pourali, Mina Maftooh, Hamed Akbarzade, Hamid Fiuji, Seyed Mahdi Hassanian and 4 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 3 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Propionate promotes CD8Journal for immunotherapy of cancer · 2026
    Article
  5. Review
  6. Artificial intelligence in pancreatic cancer: applications in early detection, tumor staging, and survival prediction-a comprehensive review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Ghazaleh Pourali *Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Danial Kazemi *Student Research Committee, Isfahan University of Medical Sciences, Hezar Jerib Street, Isfahan, Iran.
Amir Shayan Chadeganipour *School of Medicine, Isfahan University of Medical Sciences, Hezar Jerib Street, Isfahan, Iran.
Mahshid ArastonejadDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA.
Sara Naghizadeh KashaniMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Roozbeh PouraliStudent Research Committee, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran.
Mina MaftoohMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamed AkbarzadeMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid FiujiBasic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Mahdi HassanianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid Ghayour-MobarhanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsBrighton & Sussex Medical School, Department of Medical Education, Falmer, Brighton, Sussex, BN1 9PH, UK.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. avana@mums.ac.ir.
Mashhad University of Medical Sciences · IRIsfahan University of Medical Sciences · IRBrighton and Sussex Medical School · GBFerdowsi University of Mashhad · IRUniversity of Warith Al-AnbiyaaVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studying the effects of the microbiome on the development of different types of cancer has recently received increasing research attention. In this context, the microbial content of organs of the gastrointestinal tract has been proposed to play a potential role in the development of pancreatic cancer (PC). Proposed mechanisms for the pathogenesis of PC include persistent inflammation caused by microbiota leading to an impairment of antitumor immune surveillance and altered cellular processes in the tumor microenvironment. The limited available diagnostic markers that can currently be used for screening suggest the importance of microbial composition as a non-invasive biomarker that can be used in clinical settings. Samples including saliva, stool, and blood can be analyzed by 16 s rRNA sequencing to determine the relative abundance of specific bacteria. Studies have shown the potentially beneficial effects of prebiotics, probiotics, antibiotics, fecal microbial transplantation, and bacteriophage therapy in altering microbial diversity, and subsequently improving treatment outcomes. In this review, we summarize the potential impact of the microbiome in the pathogenesis of PC, and the role these microorganisms might play as biomarkers in the diagnosis and determining the prognosis of patients. We also discuss novel treatment methods being used to minimize or prevent the progression of dysbiosis by modulating the microbial composition. Emerging evidence is supportive of applying these findings to improve current therapeutic strategies employed in the treatment of PC.

Indexed as

MicrobiotaPancreatic NeoplasmsAnti-Bacterial AgentsBiomarkersDysbiosisHumansTumor MicroenvironmentAnti-Bacterial AgentsBiomarkersBiomarkerDiagnosisMicrobiomePancreatic cancerProbioticsPrognosisTreatment

Identifiers

PMID38183010
PMCPMC10768369
OpenAlexW4390608760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.